Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement

被引:186
作者
Chopra, Ian [1 ,2 ]
Schofield, Christopher [3 ,4 ]
Everett, Martin [5 ]
O'Neill, Alex [1 ,2 ]
Miller, Keith [1 ,2 ]
Wilcox, Mark [6 ]
Frere, Jean-Marie [7 ]
Dawson, Mike [8 ]
Czapiewski, Lloyd [9 ]
Urleb, Uros [10 ]
Courvalin, Patrice [11 ]
机构
[1] Univ Leeds, Fac Biol Sci, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England
[2] Univ Leeds, Fac Biol Sci, Res Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England
[3] Univ Oxford, Dept Chem, Oxford, England
[4] Univ Oxford, Oxford Ctr Mol Sci, Oxford, England
[5] Merlion Pharmaceut Pvt Ltd, Singapore, Singapore
[6] Gen Infirm, Dept Microbiol, Leeds LS1 3EX, W Yorkshire, England
[7] Univ Liege, Fac Sci, Ctr Prot Engn, Liege, Belgium
[8] Novacta Biosyst Ltd, Hatfield, Herts, England
[9] Prolysis Ltd, Yarnton, Oxon, England
[10] Lek Pharmaceut, Ljubljana, Slovenia
[11] Inst Pasteur, Unit Antibacterial Agents, Paris, France
基金
英国惠康基金;
关键词
D O I
10.1016/S1473-3099(08)70018-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This consensus statement presents the conclusions of a group of academic and industrial experts who met in London in September, 2006, to consider the issues associated with the treatment of hospital infections caused by Gram-negative bacteria. The group discussed the severe clinical problems arising from the emergence of antibiotic resistance in these bacteria and the lack of new antibacterial agents to challenge the threat. The discovery of new drugs active against hospital-acquired Gram-negative bacteria is essential to prevent a future medical and social catastrophe. An important strategy to promote drug discovery will be the development of focused cooperations between academic institutions and small pharmaceutical companies.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 76 条
[1]   Resistance to antibiotics: Are we in the post-antibiotic era? [J].
Alanis, AJ .
ARCHIVES OF MEDICAL RESEARCH, 2005, 36 (06) :697-705
[2]  
*AM SOC MICR, 2006, 46 INT CC ANT AG CHE
[3]  
*AM SOC MICR, 2007, 47 INT C ANT AG CHEM
[4]   The biological cost of mutational antibiotic resistance: any practical conclusions? [J].
Andersson, Dan I. .
CURRENT OPINION IN MICROBIOLOGY, 2006, 9 (05) :461-465
[5]  
[Anonymous], 2001, WHO GLOB STRAT CONT
[6]   Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria [J].
Appelbaum, PC ;
Jacobs, MR .
CURRENT OPINION IN MICROBIOLOGY, 2005, 8 (05) :510-517
[7]  
BAQUERO F, 2006, ANTIBIOTIC RESISTANC
[8]   Can biotech deliver new antibiotics? [J].
Barrett, JF .
CURRENT OPINION IN MICROBIOLOGY, 2005, 8 (05) :498-503
[9]   A de Novo designed inhibitor of D-Ala-D-Ala ligase from E-coli [J].
Besong, GE ;
Bostock, JM ;
Stubbings, W ;
Chopra, I ;
Roper, DI ;
Lloyd, AJ ;
Fishwick, CWG ;
Johnson, AP .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2005, 44 (39) :6403-6406
[10]   Antimicrobial resistance rising in Europe [J].
Bonn, Dorothy .
LANCET INFECTIOUS DISEASES, 2007, 7 (02) :86-86